SCHEMBL3403718

SCHEMBL3403718

Cc1ccc(-c2nc(C)c(C(=O)N3CCN(C4CCCC4)CC3)s2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.54
KDM4E B2RXH2 3/20 0.52
GAA P10253 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
THRA P10827 2/20 0.48
THRB P10828 2/20 0.48
HRH3 Q9Y5N1 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
HTR2C P28335 5/20 0.46
OXTR P30559 1/20 0.46
ACACB O00763 1/20 0.45
ACACA Q13085 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SCN5A Q14524 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN10A Q9Y5Y9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398825 0.91 SCN5A (0.54) CNR1KDM4EGAARAB9AALDH1A1
SCHEMBL3400395 0.91 CNR1 (0.52) CNR1KDM4EALDH1A1HPGDTHRA
SCHEMBL3400921 0.91 CNR1 (0.66) CNR1KDM4EGAAALDH1A1HPGD
SCHEMBL3405619 0.91 CNR1 (0.48) CNR1KDM4EGAARAB9AALDH1A1
SCHEMBL3405508 0.90 HRH3 (0.55) CNR1GAARAB9AALDH1A1HPGD
SCHEMBL3401857 0.90 CNR1 (0.51) CNR1KDM4ERAB9AALDH1A1HPGD
SCHEMBL3403938 0.90 CNR1 (0.51) CNR1KDM4EGAAALDH1A1HPGD
SCHEMBL3398438 0.90 HRH3 (0.53) CNR1KDM4EGAARAB9ATHRA
SCHEMBL13071719 0.90 HRH3 (0.53) CNR1KDM4EGAARAB9ATHRA
SCHEMBL3404388 0.89 HRH3 (0.54) CNR1GAARAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CNR1 35/4885KDM4E 3449/4885GAA 1659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.